Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [1]
- Immunohistochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-55573 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- MDH1 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- Immunogen sequence: AGQIAYSLLY SIGNGSVFGK DQPIILVLLD ITPMMGVLDG VLMELQDCAL PLLKDVIATD KEDVAFKDLD VA
- Concentration
- 0.4 mg/mL
Submitted references Utility and Mechanism of SHetA2 and Paclitaxel for Treatment of Endometrial Cancer.
Chandra V, Rai R, Benbrook DM
Cancers 2021 May 12;13(10)
Cancers 2021 May 12;13(10)
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of MDH1 in Lane 1: NIH-3T3 cell lysate (Mouse embryonic fibroblast cells); Lane 2: NBT-II cell lysate (Rat Wistar bladder tumour cells). Samples were probed using a MDH1 Polyclonal Antibody (Product # PA5-55573).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent staining of MDH1 in human cell line U-251 MG shows positivity in cytoplasm & centrosome. Samples were probed using a MDH1 Polyclonal Antibody (Product # PA5-55573).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical staining of MDH1 in human stomach tissue shows strong cytoplasmic positivity in glandular cells. Samples were probed using a MDH1 Polyclonal Antibody (Product # PA5-55573).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 Molecular mechanism of SHetA2: ( A ) Ishikawa cells were treated with SHetA2 (10 uM) for 4 h and co-immunoprecipitation was performed with mortalin antibody (Grp75)-tagged beads. Western blots (left panel) and densitometry analyses (right panel) was performed for IP3R, ALDH18A1, CTPS, MDH1, and ECHS1 to confirm the reduction of client protein co-immunoprecipitation. ( B ) Western blot analysis for the protein expression of IP3R, Cl. PARP, total caspase-3, P62, AIF, DNA damage marker (gammaH2AX) and LC3-II proteins in endometrial cancer cells treated with, or without, SHetA2 (10 uM) for 24 h. ( C ) Cell apoptosis was detected by Annexin-V/PI combined labeling with flow cytometry in endometrial cancer cells 24 h after treatment with SHetA2 (10 uM) or vehicle. ( D ) Caspase-3 activity assay for endometrial cancer cells treated with indicated dose of SHetA2 for 24 h. ** p
